Open AccessNovel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B
Author(s) -
Malecki Marek,
Sabo Chelsea,
Foorohar Afsoon,
Tombokan Xenia
Publication year - 2016
Publication title -
clinical and translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2001-1326
DOI - 10.1186/s40169-016-0111-8
Subject(s) - medicine , hepatitis b virus , immunotherapy , hbsag , breast cancer , immunity , immunology , vaccination , hepatitis b , antibody , cancer , immune system , cancer immunotherapy , virus
Background Immunotherapy of patients suffering from the human epidermal growth factor receptor 2 overexpressing (HER‐2 + ) breast cancers with the anti‐HER‐2 antibodies results in increase of the patients’ overall survival. However, no prophylactic vaccine is available against HER‐2 + breast cancers. Although, prophylactic vaccine for human hepatitis B virus (HBV) is very effective. Specific aim The specific aim of this work was to design, synthesize, and test bio‐molecules which would engage prophylactic immunity against hepatitis B virus towards killing breast cancers cells. Methods and Results By biomolecular engineering, we have created a novel family of biomolecules: antibody (anti‐HER‐2) × vaccine (HBsAg) engineered constructs (AVEC: anti‐HER‐2 × HBsAg). These biomolecules were utilized for redirecting, accelerating, and amplifying of the vaccination‐induced, prophylactic immunity originally targeted against HBV as therapeutic immunity, newly targeted against HER‐2 + breast cancers. Treatment of the HER‐2 + breast cancer cells with AVEC: anti‐HER‐2 × HBsAg in blood of the patients, vaccinated with HBsAg, rapidly increased efficacy of killing of HER‐2 + breast cancer cells over that attained with the naked anti‐HER‐2 antibodies. Conclusion Novel antibody‐vaccine engineered constructs (AVEC) facilitate redirecting, accelerating, and amplifying of prophylactic, HBV vaccination‐induced immunity as immunotherapy (RAAVIIT) of HER‐2 + breast cancer. We currently streamline this novel therapeutic paradigm into clinical trials of breast and other cancers.